Antibody titers detectable at 10 years postvaccination. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. Providers are responsible for the appropriate administration of vaccines and for ensuring patients receive vaccinations as recommended by the ACIP. Since 03-JUN-2014, the unspecified number of patients were vaccinated with improperly stored ROTATEQ (dose/frequency, route of administration were not reported). Stated that it feels like a bruise. This vaccine works by exposing you to a small dose of the virus or a protein from the virus, which causes the body to develop immunity to the disease. Administered by: Other Purchased by: Other Symptoms: Incorrect product storage, No adverse event SMQs: Write-up: This spontaneous report as received from a Medical Assistant refers to an unknown number of patients of unknown gender and ages.
Patient was not sure if he had a kidney stone or appendix pain. The patient reported that she was pregnant when she received VARIVAX (Merck). In April 2008, the patient started to have “spells”. Additional information has been requested. The patient did not have concomitant medications and on other vaccines were administered on the date of the adverse events. Other suspect therapies included unspecified influenza virus vaccine(manufacturer unknown) (strength, formulation, lot#, dose, route and duration were unspecified). identify individuals who are at risk for measles, mumps and rubella diseases, and are candidates for measles, mumps and rubella (MMR) vaccine; and recognize individuals for whom the vaccine is not appropriate; 3.
Concomitant therapies included amitriptyline hydrochloride, SYNTHROID, IMITREX and trazodone hydrochloride (reported as TRANZIDONE). Laboratory investigations and corrective treatments were not reported. She is now experiencing an itchy sensation that began 5 days after the vaccine on a spot on her back where she was affected by shingles 9 years ago. Swelling 125 mm x 120 mm. Co-suspect or concomitant therapies were not reported. Pt advised to take Diphenhydramine and to see a physician if condition worsens. The outcome was unknown.
The relatedness between the event and ZOSTAVAX was not reported. Administered by: Public Purchased by: Private Symptoms: Blister, Erythema SMQs:, Severe cutaneous adverse reactions (broad), Anaphylactic reaction (broad), Hypersensitivity (broad) Write-up: Pt noted blister + red streak on (R) arm 48 hours after immunization given no fevers. One week later (in 2007), the patient experienced shingles on her forehead. Subsequently, she transmitted the herpes zoster virus to her husband which was at home as a bon marrow transplant patient. Patient fine until late Saturday (approx 11:00 PM). Administered by: Other Purchased by: Other Symptoms: Injection site bruising, Injection site discolouration, Injection site erythema, Injection site induration, Injection site swelling SMQs:, Haemorrhage terms (excl laboratory terms) (narrow), Extravasation events (injections, infusions and implants) (broad), Haemodynamic oedema, effusions and fluid overload (narrow) Write-up: Client given SQ injection of ZOSTAVAX on 6-19-15. He also had difficulty walking.
Administered by: Unknown Purchased by: Private Symptoms: Erythema, Pruritus, Skin warm SMQs:, Anaphylactic reaction (broad), Hypersensitivity (broad) Write-up: 1-2″ red, hot to touch, itchy area. The patient experienced an unspecified severe allergic reaction after receiving TDAP.